PMID- 27134695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240325
IS  - 1938-1247 (Print)
IS  - 1938-1247 (Electronic)
IS  - 1938-1247 (Linking)
VI  - 7
IP  - 2
DP  - 2015
TI  - mTOR Inhibitors at a Glance.
PG  - 15-20
AB  - Mechanistic target of rapamycin (mTOR) is a conserved threonine and serine 
      protein kinase that was identified more than two decades ago as the target of 
      immunosuppressive drug rapamycin. Since then considerable amount of information 
      has been learned about the function of this kinase. It is now well-established 
      that mTOR plays a pivotal role in governing cell growth and proliferation, hence 
      making mTOR a therapeutic target for disease conditions caused by deregulated 
      cell proliferation, such as cancer. In the past decade, numerous mTOR inhibitors 
      have been developed and many are currently in clinical trials for cancer 
      treatment. This commentary is to provide a brief summary of these mTOR 
      inhibitors.
FAU - Zheng, Yin
AU  - Zheng Y
AD  - Medical Health Care Center, Hainan Provincial People's Hospital, Haikou, China.
FAU - Jiang, Yu
AU  - Jiang Y
AD  - Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, 
      Pittsburgh, Pennsylvania.
LA  - eng
GR  - R21 CA169186/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Mol Cell Pharmacol
JT  - Molecular and cellular pharmacology
JID - 101516660
PMC - PMC4849280
MID - NIHMS761600
OTO - NOTNLM
OT  - Akt
OT  - Kinase inhibitors
OT  - Phosphatidylinositol-3-kinase
OT  - Rapamycin
OT  - mTOR
COIS- Conflicts of Interest The authors have no conflicts of interest to declare.
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2016/04/28
CRDT- 2016/05/03 06:00
PHST- 2016/05/03 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2016/04/28 00:00 [pmc-release]
PST - ppublish
SO  - Mol Cell Pharmacol. 2015;7(2):15-20.